These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19067990)

  • 1. Four cases of venous thromboembolism associated with olanzapine.
    Maly R; Masopust J; Hosak L; Urban A
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):116-8. PubMed ID: 19067990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.
    Srivastava A; Borkar HA; Chandak S
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):119-21. PubMed ID: 19067992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.
    Carrizo E; Fernández V; Quintero J; Connell L; Rodríguez Z; Mosquera M; Acosta A; Baptista T
    Schizophr Res; 2008 Aug; 103(1-3):83-93. PubMed ID: 18436434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver toxicity due to olanzapine.
    Domínguez-Jiménez JL; Puente-Gutiérrez JJ; Pelado-García EM; Cuesta-Cubillas D; García-Moreno AM
    Rev Esp Enferm Dig; 2012 Dec; 104(11):617-8. PubMed ID: 23368661
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.
    Toki S; Morinobu S; Yoshino A; Yamawaki S
    J Clin Psychiatry; 2004 Nov; 65(11):1576-7. PubMed ID: 15554776
    [No Abstract]   [Full Text] [Related]  

  • 6. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study.
    Parker C; Coupland C; Hippisley-Cox J
    BMJ; 2010 Sep; 341():c4245. PubMed ID: 20858909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Massive pulmonary emboli associated with olanzapine.
    Hilli MA; MacRedmond R; Hollywood P; O'Neill S; Morgan R
    Ir Med J; 2008 Jun; 101(6):186. PubMed ID: 18700515
    [No Abstract]   [Full Text] [Related]  

  • 8. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment.
    Oglodek E; Szota A; Araszkiewicz A
    Aust N Z J Psychiatry; 2013 Oct; 47(10):972. PubMed ID: 23630396
    [No Abstract]   [Full Text] [Related]  

  • 10. A patient treated with olanzapine developing diabetes de novo: proposal for hyperglycaemia screening.
    Duiverman ML; Cohen D; van Oven W; Nieboer P
    Neth J Med; 2007 Oct; 65(9):346-8. PubMed ID: 17954954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypothermia under olanzapine treatment: clinical case series and review of current literature].
    Kreuzer P; Landgrebe M; Wittmann M; Hajak G; Schecklmann M; Poeppl TB; Langguth B
    Nervenarzt; 2012 May; 83(5):630-7. PubMed ID: 21626387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal pulmonary embolism following antipsychotic treatment and physical restraint.
    Hewer W; Kauder E; Vierling P
    Pharmacopsychiatry; 2009 Sep; 42(5):206-8. PubMed ID: 19724986
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia.
    Stip E; Langlois R; Thuot C; Mancini-Marïe A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):297-300. PubMed ID: 16978752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine and venous thromboembolism.
    Hägg S; Tätting P; Spigset O
    Int Clin Psychopharmacol; 2003 Sep; 18(5):299-300. PubMed ID: 12920392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolongation of clozapine-induced leukopenia with olanzapine treatment.
    Sayin A; Cosar B
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):958-9. PubMed ID: 16631295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions.
    Hägg S; Bate A; Stahl M; Spigset O
    Drug Saf; 2008; 31(8):685-94. PubMed ID: 18636787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
    Peuskens J; De Hert M; Mortimer A;
    Int Clin Psychopharmacol; 2007 May; 22(3):145-52. PubMed ID: 17414740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotics and the risk of venous thromboembolism.
    Liperoti R; Gambassi G
    BMJ; 2010 Sep; 341():c4216. PubMed ID: 20858908
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.
    Birkenaes AB; Birkeland KI; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2009 Apr; 29(2):109-16. PubMed ID: 19512971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.